Mullan’s Alzheimer Research Team Developed Nilvadipine

FOR IMMEDIATE RELEASE
Sarasota, Florida, United States of America (Free-Press-Release.com) January 27, 2012 --

Nilvadipine is an Alzheimer’s drug that was recently developed by a research team led by Dr. Michael Mullan- the Director of Roskamp Institute. Dr. Mullan and his fellow scientists have been trying to find the causes and cures for Alzheimer’s disease for over 20 years, moving from the United Kingdom to Florida and then to Sarasota to establish Roskamp Institute. Nilvadipine has been selected for funding and large-scale European clinical trial, and Roskamp Institute will provide research support for the trial, such as evaluating genetic and other signs for the disease in participants. As announced by an international research consortium led by the Trinity College Dublin, Ireland, more than 500 people will take part in this multi-center phase III clinical trial especially designed to examine the effectiveness of drug.

Dr. Mullan’s Alzheimer research team consisted of lead scientist Daniel Paris, Ph. D. and Associate Director Fiona Crawford, Ph.D. This study will be funded by European Commission Seventh Framework Program and over twenty European clinical sites will participate in the trial. As per Dr. Mullan, the study findings of these trials will help speed up the process for getting approval from the United States Food and Drug Administration (FDA). The drug has already been approved for use in the mild cases of hypertension or high blood pressure.

About Dr Michael Mullan

Dr Michael Mullan has been working in the biomedical field for many years. He is a leading researcher with special expertise in assessment of the earliest cognitive symptoms and stages of Alzheimer’s disease. Mullan’s Alzheimer research works are also published in various articles which help students and researchers for making new discoveries. Find out more about his Alzheimer research works, by browsing through www.rfdn.org or www.mullanalzheimer.com or www.mullanalzheimer.info.

MULLAN ALZHEIMER